US-based Endonovo Therapeutics, Inc., a medical device company known for its innovative and effective pain management solutions, has announced that it is entering the final stages of clearance to receive a Taiwan FDA (TFDA) License for Medical Devices to distribute its flagship product, SofPulse in Taiwan.

Sofpulse medical devices are designed to accelerate recovery and reduce pain and oedema post operatively. SofPulse technology uses a non-invasive Pulsed Electro-Magnetic Field (PEMF) therapy that uses low-frequency electromagnetic fields to stimulate the body's natural healing processes, stimulate circulation and speed up the healing process.

With its launch in Taiwan on the horizon, Sofpulse is poised to help more patients experience the benefits of this revolutionary technology. Endonovo Therapeutics has partnered with Taiwan-based distributor Evermed Medical Enterprises Co.

"Our sales and distribution offices and teams are strategically located throughout Taiwan, which allows us to effectively service Taiwan's 23 million population, hospitals and medical centres", said Evermed’s Chief Executive Officer, George Wang.

Clinical studies have demonstrated that SofPulse helps reduce pain and oedema (swelling), promote bone and soft tissue repair and decrease the need for opioids and other pain medications.